Deep sector expertise across pharmaceuticals, medical devices, hospital networks, health insurance, and digital health — across India, Southeast Asia, and the GCC where healthcare markets are being built from the ground up.
Market sizing for specialty and generic pharmaceuticals, pricing dynamics, KOL mapping, physician prescribing behaviour, and competitive positioning across regulated and semi-regulated markets.
Hospital procurement behaviour, clinical adoption barriers, price-value analysis, and competitive benchmarking for diagnostic equipment, surgical tools, and point-of-care technology.
Catchment analysis, patient flow mapping, specialty mix optimisation, and M&A due diligence for hospital chains, multi-specialty clinics, and day care surgery centres across South Asia.
Consumer willingness to pay, employer-sponsored health benefit design, claims behaviour benchmarking, and distribution channel strategy across India's rapidly formalising health insurance market.
Telemedicine adoption curves, health app engagement benchmarks, EHR landscape mapping, and investor-ready market sizing for digital health platforms entering South and Southeast Asian markets.
Pet healthcare spending behaviour, livestock health product demand, veterinary practice landscape, and market entry strategy for animal pharmaceutical and nutrition companies entering Asian markets.
These are the actual questions clients bring to us. We've answered some version of each of them, multiple times, across multiple geographies.
A global oncology group sought to establish a 12-city network in India. NEO conducted patient flow analysis, physician interviews, and payor landscape research across 8 Tier 1 and Tier 2 cities. Board approved phased entry in 6 weeks.
European surgical robotics company mapping Southeast Asian market entry. Hospital readiness assessment, surgeon KOL mapping, and reimbursement landscape analysis across Singapore, Thailand, and Indonesia.
Commercial due diligence on a 12-hospital chain acquisition. Occupancy validation, payor mix verification, and physician retention risk assessment. Two material misrepresentations surfaced, leading to deal restructuring.
20 years in healthcare strategy and consulting. Led 50+ market entry and M&A mandates across pharmaceuticals, hospitals, and MedTech in South and Southeast Asia. Former BCG.
25+ engagements across branded and generic pharmaceuticals, clinical research organisations, and diagnostic companies. Specialist in physician research methodologies and KOL strategy.
Specialist in GCC healthcare regulatory and investment environments. 12 years advising international healthcare groups on market entry across UAE, KSA, and Qatar.
Choose the access level that suits your organisation. All licences include the full report, methodology appendix, and structured data tables. Post-sale analyst support included.